Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

(2018) Michael Y. Choi et al.   Cell Stem Cell

Venetoclax: A new wave in hematooncology

(2018) Jana Mihalyova et al.   EXPERIMENTAL HEMATOLOGY

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells

(2018) M. Hojjat-Farsangi et al.   LEUKEMIA

MicroRNAdysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia

(2017) Laura Z. Rassenti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib

(2016) J Yu et al.   LEUKEMIA

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

(2016) S Eldfors et al.   LEUKEMIA

Identification of Noncanonical Wnt Receptors Required for Wnt-3a-Induced Early Differentiation of Human Neural Stem Cells

(2016) Nora Bengoa-Vergniory et al.   MOLECULAR NEUROBIOLOGY

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment

(2016) Y Sun et al.   ONCOGENE

Wnt5a Signaling in Cancer

(2016) Marwa Asem et al.   Cancers

Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia

(2015) M. Muschen   BLOOD

Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia

(2015) Huimin Geng et al.   CANCER CELL

Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia

(2015) P. Janovska et al.   CLINICAL CANCER RESEARCH

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

(2015) Jian Yu et al.   JOURNAL OF CLINICAL INVESTIGATION

Regulation of hematopoiesis by activators and inhibitors of Wnt signaling from the niche

(2014) Christina Schreck et al.   Annals of the New York Academy of Sciences

ROR1, an embryonic protein with an emerging role in cancer biology

(2014) Nicholas Borcherding et al.   Protein & Cell

Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells

(2014) C. Berger et al.   Cancer Immunology Research

A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties

(2013) James M. Murphy et al.   BIOCHEMICAL JOURNAL

Receptor tyrosine kinases with intracellular pseudokinase domains

(2013) Jeannine M. Mendrola et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

(2013) T. Pemovska et al.   Cancer Discovery

Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia

(2012) Vincent T. Bicocca et al.   CANCER CELL

Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells

(2012) A H Daneshmanesh et al.   LEUKEMIA

Correction: Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model

(2012) Bhuvanesh Dave et al.   PLoS One

Single-vector inducible lentiviral RNAi system for oncology target validation

(2011) Dmitri Wiederschain et al.   CELL CYCLE

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome

(2010) R. C. Harvey et al.   BLOOD

Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors

(2010) L. Grumolato et al.   GENES & DEVELOPMENT

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia

(2009) H. Kang et al.   BLOOD

Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia

(2009) T. Burmeister et al.   HAEMATOLOGICA

β-catenin is involved in N-cadherin–dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1–positive B acute lymphoblastic leukemia cells

(2008) Marit Kveine Nygren et al.   EXPERIMENTAL HEMATOLOGY

PTEN-deficient cancers depend on PIK3CB

(2008) S. Wee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA